AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7128841
Drug: Modicon tablets
RxNorm normalized name: Medicone
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modicon tablets
Trial: 7128841
Drug: Lowest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest dose product (unspecified)
Trial: 28885402
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA); given within 3 hours after delivery; specific dosage not mentioned.
Trial: 28885402
Drug: Prophylactic TXA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic TXA; specific dosage and duration not mentioned.
Trial: 17562974
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg daily
Trial: 17562974
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg daily
Trial: 15330493
Drug: Hyben Vital
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyben Vital 5 g daily
Trial: 7986974
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day for one week
Trial: 7986974
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day for one week followed by clarithromycin 1 g/day for 2 weeks (group B)
Trial: 7986974
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day for one week followed by tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group C)
Trial: 7986974
Drug: Tripotassium dicitrato
RxNorm normalized name: Tripotassium dicitratobismuthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group D)
Trial: 1091148
Drug: Human placental
RxNorm normalized name: Human Placental Tissue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human placental lactogen (HPL) treatment group
Trial: 31814335
Drug: Enzyme Replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme Replacement Therapy (ERT) in CLN2 disease patients
Trial: 31814335
Drug: Neurofilament light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofilament light levels before treatment in CLN2 disease patients
Trial: 24077199
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic with steroids
Trial: 20687845
Drug: CDA lotion
RxNorm normalized name: 2-CdA
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDA lotion (non-irritating hydrating lotion)
Trial: 20687845
Drug: CDA lotion
RxNorm normalized name: 2-CdA
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDA lotion (twice-daily application for 4 days)
Trial: 20687845
Drug: CDA lotion
RxNorm normalized name: 2-CdA
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDA lotion
Trial: 19638365
Drug: Aggressive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive statin administration before percutaneous coronary intervention (PCI)
Trial: 15210501
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (OD) gentamicin regimen
Trial: 15210501
Drug: Multi-dose (MD)
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose (MD) gentamicin regimen
Trial: 8705090
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release tablet of 300 mg theophylline
Trial: 8705090
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose equivalent to 131.46 mg theophylline
Trial: 1324637
Drug: Daptomycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (3 mg/kg body weight)
Trial: 1324637
Drug: Vancomycin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1,000 mg)
Trial: 25081651
Drug: Tiotropium 1.25
RxNorm normalized name: TIOTROPIUM 1.25MCG/ACTUAT 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 1.25 μg
Trial: 25081651
Drug: Tiotropium 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 5 μg, 1.25 μg, 2.5 μg
Trial: 20947881
Drug: Clarithromycin sequential
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin sequential therapy
Trial: 20947881
Drug: Levofloxacin-250 sequential
RxNorm normalized name: levofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-250 sequential therapy
Trial: 20947881
Drug: Levofloxacin-500 sequential
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-500 sequential therapy
Trial: 12548273
Drug: 3‐in‐1 nerve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐in‐1 nerve block with bupivacaine plus intravenous morphine
Trial: 11031221
Drug: Front-loaded regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-loaded regimen of clopidogrel (300 mg the first day and 75 mg/d for the next 7 days)
Trial: 11031221
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of clopidogrel (75 mg/d for 8 days)
Trial: 8898135
Drug: Unscrubbed, ungowned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unscrubbed, ungowned leg holder during preparation and draping
Trial: 8898135
Drug: Scrubbed and
RxNorm normalized name: Scrub-Stat
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scrubbed and gowned leg holder during preparation and draping
Trial: 8898135
Drug: General air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General air counts during preparation and draping
Trial: 6360597
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg, administered orally 30 min prior to the test meal.
Trial: 31977907
Drug: Moxibustion (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion (twice weekly for 4 weeks at acupuncture points SP6, LR3, and CV4) plus conventional medication for 4 weeks, followed by conventional medication alone for 8 weeks.
Trial: 31977907
Drug: Moxibustion plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion plus conventional medication.
Trial: 31977907
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medication alone.
Trial: 30885027
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention (dexmedetomidine 1 µg/kg IV 15 minutes before anesthesia induction and bilateral transversus abdominis plane block with 0.375% ropivacaine 30 mL)
Trial: 27466608
Drug: Orange maize
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange maize delivering 600 μg retinol equivalents (REs)/d as carotenoid plus placebo (OM)
Trial: 27466608
Drug: Low‐carotenoid white
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐carotenoid white maize plus 600 μg REs/d as retinyl palmitate (VA)
Trial: 12072066
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% methylprednisolone
Trial: 12072066
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% dexpanthenol
Trial: 10500778
Drug: Quinine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (30 mg/kg/day)
Trial: 3529538
Drug: Aspirin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (25 mg/kg/day for 24 hours in four equally divided doses)
Trial: 3529538
Drug: Placebo (starch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch, 25 mg/kg/day for 24 hours in four equally divided doses)
Trial: 31725697
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable Acuvue Oasys (AODD)
Trial: 12873325
Drug: LifeSPAN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LifeSPAN therapy
Trial: 9533167
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy administered once every one or two weeks or several-times-daily
Trial: 9533167
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy (general)
Trial: 7999650
Drug: Epidural alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural alfentanil 500 micrograms in 10 mL 0.125% bupivacaine, followed by continuous infusion of alfentanil 20 micrograms/mL in 0.125% bupivacaine
Trial: 7999650
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 micrograms in 10 mL 0.125% bupivacaine, followed by continuous infusion of fentanyl 2 micrograms/mL in 0.125% bupivacaine
Trial: 25882438
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-Rich Plasma (PRP) - 3 injections of 1 mL
Trial: 25882438
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) - 3 injections of 1 mL
Trial: 8881885
Drug: Low-energy extracorporal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy extracorporal shock wave therapy (3000 impulses of 0.08 mJ/mm2)
Trial: 8267195
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia combined with patient‐controlled intravenous morphine (GA)
Trial: 3710294
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (60 mg daily)
Trial: 22068670
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - no treatment (n = 250)
Trial: 17564408
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate 9 g nightly
Trial: 17564408
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate 6 g and 9 g nightly
Trial: 17564408
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (all doses)
Trial: 12244893
Drug: Enteroplant (enteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteroplant (enteric coated capsules containing 90 mg peppermint oil and 50 mg caraway oil each)
Trial: 12244893
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulation (5 capsules containing 36 mg peppermint oil and 20 mg caraway oil each)
Trial: 12244893
Drug: Enteroplant (enteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteroplant (enteric coated capsules)
Trial: 12244893
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulation
Trial: 9889031
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 every 28 days for five cycles
Trial: 9889031
Drug: Epidoxorubicin 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidoxorubicin 120 mg/m2 iv plus paclitaxel 150 mg/m2 iv every 28 days
Trial: 7484887
Drug: Perindopril (4‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4‐8 mg orally) with possible addition of isradipine (5‐10 mg orally) and hydralazine if necessary
Trial: 1791799
Drug: Ambroxol (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (intravenous infusion)
Trial: 1791799
Drug: Tokio‐Akita (TA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tokio‐Akita (TA) surfactant (endotracheal administration)
Trial: 1791799
Drug: Placebo (endotracheal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (endotracheal administration)
Trial: 31398441
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg caffeine (placebo)
Trial: 18984662
Drug: 240 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg/d oral iron alone
Trial: 18984662
Drug: 240 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg/d oral iron plus 75 microg/d levothyroxine
Trial: 16893507
Drug: Insulin drip
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin drip
Trial: 8313865
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg bid)
Trial: 8313865
Drug: Amoxicillin/clavulanate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (500 mg tid)
Trial: 3091629
Drug: Continuous GHRH
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous GHRH infusion (0.15 microgram/kg X h for 5 h, followed by 0.75 microgram/kg X h for 5 h)
Trial: 3091629
Drug: Single GHRH
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single GHRH bolus dose (1 microgram/kg, iv) after continuous GHRH infusion
Trial: 29557398
Drug: Augmentation procedures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation procedures
Trial: 21891773
Drug: Extra high-volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra high-volume hemofiltration (EHVHF) at 85 mL/kg/h
Trial: 21891773
Drug: High-volume hemofiltration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume hemofiltration (HVHF) at 50 mL/kg/h
Trial: 20358276
Drug: GES-scoring plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GES-scoring plus sHLA-G expression (Group B)
Trial: 17974605
Drug: Intra-arterial contrast
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial contrast injection (IACTA)
Trial: 17974605
Drug: Conventional CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CT angiography with intravenous contrast injection (IVCTA)
Trial: 10612135
Drug: Arthroscopically assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopically assisted bone‐tendon‐bone A.C.L. reconstruction
Trial: 10612135
Drug: Open procedure
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open procedure A.C.L. reconstruction
Trial: 2024559
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with epinephrine (5 micrograms.ml‐1)
Trial: 23754514
Drug: Darexaban-MR 120
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darexaban-MR 120 mg qd + digoxin 0.25 mg qd
Trial: 23754514
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + digoxin 0.25 mg qd
Trial: 19574992
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg/kg premedication
Trial: 10743479
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet each day
Trial: 10743479
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms folic acid and placebo tablets on alternate days
Trial: 7723371
Drug: LPD (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPD (epirubicin 15-40 mg/m2 and Lipiodol 0.02-0.25 ml/kg)
Trial: 2386364
Drug: Intravenous cefetamet
RxNorm normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefetamet
Trial: 2386364
Drug: Oral cefetamet
RxNorm normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cefetamet pivoxil
Trial: 7150459
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg every 6 h for 4 days)
Trial: 24947926
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus vismodegib (VIS)
Trial: 19717243
Drug: Behavioral Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Family Counseling (BFC) plus Individual-Based Treatment (IBT)
Trial: 19717243
Drug: Individual-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-Based Treatment (IBT) alone
Trial: 14633758
Drug: 30% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oxygen with droperidol 0.625 mg
Trial: 8682157
Drug: Calculated activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated activity to deliver a thyroid dose of 100 Gy
Trial: 6763202
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg + Codeine 60 mg
Trial: 6763202
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg + Codeine 60 mg
Trial: 28058962
Drug: Lidocaine (LI)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (LI) injection
Trial: 23475164
Drug: Nitrate-rich concentrated
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich concentrated beetroot juice (BR; 2 × 250 mL·d, ∼8.2 mmol·d nitrate)
Trial: 23475164
Drug: Nitrate-depleted BR
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-depleted BR placebo (PL; 2 × 250 mL·d, ∼0.006 mmol·d nitrate)
Trial: 19407730
Drug: Desvenlafaxine (50-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (50-400 mg/day)
Trial: 19407730
Drug: Desvenlafaxine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (400 mg/day)
Trial: 17217572
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Ca/d
Trial: 17217572
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg Ca/d
Trial: 15060225
Drug: Medication algorithm-medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication algorithm-medication alone (MedMgt)
Trial: 15060225
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Comb)
Trial: 15060225
Drug: Community comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community comparison (CC)
Trial: 15060225
Drug: Med/NoMed (stopping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Med/NoMed (stopping medication)
Trial: 15060225
Drug: Med/Med (consistent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Med/Med (consistent medication use)
Trial: 15060225
Drug: NoMed/Med (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NoMed/Med (starting medication)
Trial: 15060225
Drug: NoMed/NoMed (never
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NoMed/NoMed (never reported medication use)
Trial: 9676863
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 2 microg kg(‐1)
Trial: 7848364
Drug: Cotrimoxazole preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole preparations and placebo
Trial: 7848364
Drug: Multivitamin preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin preparations and placebo
Trial: 3261612
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (active treatment)
Trial: 30980569
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine practices in obstetrics
Trial: 28686675
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg added after each IFNβ injection for 4 weeks
Trial: 28686675
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to the standard treatment for FLS for 4 weeks
Trial: 23701059
Drug: Intraparenchymal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraparenchymal blood patch
Trial: 23701059
Drug: Intraparenchymal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraparenchymal blood patch with 19-gauge needle
Trial: 23701059
Drug: Intraparenchymal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraparenchymal blood patch with 17-gauge needle